"Despite continued tough economic conditions worldwide, China Biologic continues to prosper due to favorable industry fundamentals, growing brand recognition, a solid business strategy and a highly defensible, scalable business model," remarked Mr. Zhao. "We see 2009 as a year in which we attain critical mass, and realize significant economies of scale as we integrate our acquisitions and increase our capacity utilization."
China Biologic will host a conference call at 8:00 a.m. EDT on Tuesday, May 19, 2009, to discuss the 2009 first quarter financial results. To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 1-888-419-5570. International callers should dial +1-617-896-9871. The pass code for the call is 634 701 69. If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Tuesday, May 19, 2009 at 10:00 a.m. EDT. To access the replay, dial 1- 888-286-8010. International callers should dial +1-617-801-6888. The conference pass code is 373 105 74.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect
majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and
equity investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing
Dalin Biologic Technologies Co., Ltd. is currently the largest non-state-owned
plasma-based biopharmaceutical company approved by the Chinese government.
The Company is a fully integrated biologic products company with plasma
collection, production and manufacturing, research and development, and
commercial operations. The Company's blood products are irreplaceable in the
application of medical emergencies, and prevention and treatment for various
diseases. It sells its plasm
|SOURCE China Biologic Products, Inc.|
Copyright©2009 PR Newswire.
All rights reserved